Aerie pharmaceuticals announces publication of peer-reviewed paper evaluating the treatment effect of netarsudil on outflow function in steroid-induced glaucoma

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the publication of a peer-reviewed paper in elife, a science journal, entitled, “antifibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure h
AERI Ratings Summary
AERI Quant Ranking